However, they differ in a key way: tirzepatide is a dual agonist (GLP-1 and GIP), while retatrutide is a triple agonist (GLP-1, GIP, and GCG)
However, this proves to be more complex and requires careful dose adjustment
As mentioned by Lingvay et al., semaglutide has shown promise as a treatment option for non-diabetics with established atherosclerotic disease by reducing their risk of MACE by 20% despite having varying HBA1c baselines [47]
Your provider can also work with you to adjust to medication changes safely
Built for Subscription and Lifetime Value Models
However, a significant challenge in evaluating kidney outcomes lies in the inconsistent definitions of renal endpoints across studies, particularly regarding the thresholds for substantial eGFR decline, which vary from 30% to 57%